Daniel Chubb
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daniel Chubb has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Richard S. Houlston
Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK
46 shared publications - Alex J. Cornish
Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK
44 shared publications - Ben Kinnersley
Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK
42 shared publications - David C. Wedge
Manchester Cancer Research Centre, The University of Manchester, Manchester, UK
42 shared publications - Amit Sud
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
41 shared publications - Andreas J. Gruber
University of Konstanz, Konstanz, Germany
41 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S18 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Table S18: Regression - Mitochondria Count (Log10). Linear regression was applied. All results are adjusted by sex, age of sampling and stage. Results with P < 0.05 are highlighted. ChRCC, chromophobe renal cell carcinoma; CN, copy number state; LoH, loss of heterozygosity; MB, megabase; pRCC, papillary renal cell carcinoma; SNV, single nucleotide variant; SV, structural variant.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S18 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Table S18: Regression - Mitochondria Count (Log10). Linear regression was applied. All results are adjusted by sex, age of sampling and stage. Results with P < 0.05 are highlighted. ChRCC, chromophobe renal cell carcinoma; CN, copy number state; LoH, loss of heterozygosity; MB, megabase; pRCC, papillary renal cell carcinoma; SNV, single nucleotide variant; SV, structural variant.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Table S8: Summary of recurrent structural variant events. ChRCC, chromophobe renal cell carcinoma; SV, structural variant.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Table S8: Summary of recurrent structural variant events. ChRCC, chromophobe renal cell carcinoma; SV, structural variant.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S16 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Table S16: Clinical Correlations with age, sex, stage and grade. Patient sex uses female sex as baseline. Results with P < 0.05 are highlighted. ChRCC, chromophobe renal cell carcinoma; CN, copy number state; LoH, loss of heterozygosity; MB, megabase; pRCC, papillary renal cell carcinoma; SNV, single nucleotide variant; SV, structural variant.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S16 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Table S16: Clinical Correlations with age, sex, stage and grade. Patient sex uses female sex as baseline. Results with P < 0.05 are highlighted. ChRCC, chromophobe renal cell carcinoma; CN, copy number state; LoH, loss of heterozygosity; MB, megabase; pRCC, papillary renal cell carcinoma; SNV, single nucleotide variant; SV, structural variant.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
The identification of cancer drivers is a cornerstone to the delivery of precision oncology. So far, sequencing of renal cell cancer (RCC) has largely been confined to the clear cell subtype of RCC. In contrast, sequencing analyses of the less common forms of RCC, papillary RCC (pRCC) and chromophobe RCC (ChRCC), have so far been limited. We analyzed whole-genome sequencing data on 164 tumor–normal pairs from the Genomics England 100,000 Genomes Project, providing a comprehensive, high-resolution map of copy number alterations, structural variation, and key global genomic features, including mutational signatures, intratumor heterogeneity, and analysis of extrachromosomal DNA formation. Our research establishes correlations between genomic alterations and histologic diversification and the extent to which genetically-mediated immune escape contributes to the development of these RCC subtypes.Implications:We demonstrate the distinctive genetics that characterizes pRCC and ChRCC and how this information has the potential to inform patient treatment and clinical trials.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
The identification of cancer drivers is a cornerstone to the delivery of precision oncology. So far, sequencing of renal cell cancer (RCC) has largely been confined to the clear cell subtype of RCC. In contrast, sequencing analyses of the less common forms of RCC, papillary RCC (pRCC) and chromophobe RCC (ChRCC), have so far been limited. We analyzed whole-genome sequencing data on 164 tumor–normal pairs from the Genomics England 100,000 Genomes Project, providing a comprehensive, high-resolution map of copy number alterations, structural variation, and key global genomic features, including mutational signatures, intratumor heterogeneity, and analysis of extrachromosomal DNA formation. Our research establishes correlations between genomic alterations and histologic diversification and the extent to which genetically-mediated immune escape contributes to the development of these RCC subtypes.Implications:We demonstrate the distinctive genetics that characterizes pRCC and ChRCC and how this information has the potential to inform patient treatment and clinical trials.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S15 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Table S15: Summary of mutations explained by COSMIC signatures. Signatures which are suspected to be signature artifacts are not included. Percentage of mutation burden refers to the percentage of either the total single base substitutions (SBS) or indels (ID) explained by a COSMIC signature for each patient. ChRCC, chromophobe renal cell carcinoma; ID1, slippage during DNA replication of the replicated DNA strand; ID2, slippage during DNA replication of the replicated DNA strand; ID12, unknown aetiology; pRCC, papillary renal cell carcinoma SBS1, spontaneous deamination of 5-methylcytosine (clock-like signature); SBS5, unknown (clock-like signature); SBS26, defective DNA mismatch repair; SBS44, defective DNA mismatch repair.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S15 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Table S15: Summary of mutations explained by COSMIC signatures. Signatures which are suspected to be signature artifacts are not included. Percentage of mutation burden refers to the percentage of either the total single base substitutions (SBS) or indels (ID) explained by a COSMIC signature for each patient. ChRCC, chromophobe renal cell carcinoma; ID1, slippage during DNA replication of the replicated DNA strand; ID2, slippage during DNA replication of the replicated DNA strand; ID12, unknown aetiology; pRCC, papillary renal cell carcinoma SBS1, spontaneous deamination of 5-methylcytosine (clock-like signature); SBS5, unknown (clock-like signature); SBS26, defective DNA mismatch repair; SBS44, defective DNA mismatch repair.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Figure S11: Significant genomic alterations in ChRCC (n = 59). Alterations are highlighted in grey. Each column represents a sample.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Figure S11: Significant genomic alterations in ChRCC (n = 59). Alterations are highlighted in grey. Each column represents a sample.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S11 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Table S11: Summary table of non-coding drivers. Only results with Q < 0.05 in either OncodriveFML or ActiveDriverWGSR are displayed. Only non-hypermutated samples are included. ChRCC,: chromophobe renal cell carcinoma; pRCC, papillary renal cell carcinoma; SNV, single nucleotide variant.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S11 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Table S11: Summary table of non-coding drivers. Only results with Q < 0.05 in either OncodriveFML or ActiveDriverWGSR are displayed. Only non-hypermutated samples are included. ChRCC,: chromophobe renal cell carcinoma; pRCC, papillary renal cell carcinoma; SNV, single nucleotide variant.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Figure S2: Overview of stage two of the copy-number-alteration-calling pipeline. SNV, single nucleotide variant; VAF, variant allele frequency.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Figure S2: Overview of stage two of the copy-number-alteration-calling pipeline. SNV, single nucleotide variant; VAF, variant allele frequency.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Table S7: Summary of recurrent copy number alteration focal regions. Recurrent focal regions were selected based on significance threshold Q < 0.05 from GISTIC output. Q values were segregated by CNA type. CNA, copy number alteration; MB, megabase; pRCC, papillary renal cell carcinoma.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Table S7: Summary of recurrent copy number alteration focal regions. Recurrent focal regions were selected based on significance threshold Q < 0.05 from GISTIC output. Q values were segregated by CNA type. CNA, copy number alteration; MB, megabase; pRCC, papillary renal cell carcinoma.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Figure S6a-b: Differences in arm-level copy-number alterations (CNA) between (a) classical (n = 48) and (b) eosinophilic (n = 13) ChRCC subtypes.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Figure S6a-b: Differences in arm-level copy-number alterations (CNA) between (a) classical (n = 48) and (b) eosinophilic (n = 13) ChRCC subtypes.